Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Assets Average (2016 - 2025)

Celldex Therapeutics has reported Assets Average over the past 15 years, most recently at $615.7 million for Q4 2025.

  • Quarterly results put Assets Average at $615.7 million for Q4 2025, down 23.78% from a year ago — trailing twelve months through Dec 2025 was $615.7 million (down 23.78% YoY), and the annual figure for FY2025 was $687.7 million, up 9.33%.
  • Assets Average for Q4 2025 was $615.7 million at Celldex Therapeutics, down from $670.4 million in the prior quarter.
  • Over the last five years, Assets Average for CLDX hit a ceiling of $857.2 million in Q2 2024 and a floor of $211.8 million in Q2 2021.
  • Median Assets Average over the past 5 years was $423.9 million (2022), compared with a mean of $503.3 million.
  • Biggest five-year swings in Assets Average: decreased 24.94% in 2023 and later skyrocketed 187.93% in 2024.
  • Celldex Therapeutics' Assets Average stood at $452.4 million in 2021, then decreased by 20.21% to $361.0 million in 2022, then increased by 3.31% to $372.9 million in 2023, then surged by 116.59% to $807.8 million in 2024, then dropped by 23.78% to $615.7 million in 2025.
  • The last three reported values for Assets Average were $615.7 million (Q4 2025), $670.4 million (Q3 2025), and $715.9 million (Q2 2025) per Business Quant data.